Related Experiment Videos
Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial
W O Monteiro1, H F Noshirvani, I M Marks
1Institute of Psychiatry, De Crespigny Park, London.
Summary
Clomipramine, used for obsessive-compulsive disorder, significantly caused anorgasmia in patients. This sexual dysfunction persisted and affected both men and women, impacting treatment effectiveness.
Area of Science:
- Psychiatry
- Pharmacology
- Sexual Medicine
Background:
- Obsessive-compulsive disorder (OCD) is a mental health condition often treated with medication.
- Sexual dysfunction is a potential side effect of psychiatric medications, but may be underreported.
Purpose of the Study:
- To investigate the impact of clomipramine on sexual function in patients with OCD.
- To assess the incidence and persistence of sexual side effects, specifically anorgasmia.
Main Methods:
- A double-blind, placebo-controlled study involving 46 patients diagnosed with OCD.
- Structured interviews were conducted to assess changes in sexual function.
Main Results:
- Of 33 patients with normal sexual function at baseline, 24 (73%) taking clomipramine developed partial or total anorgasmia.
- None of the 9 patients receiving placebo experienced anorgasmia.
- Anorgasmia persisted with minimal tolerance over five months of clomipramine treatment, affecting men and women equally.
Conclusions:
- Clomipramine is associated with a high incidence of anorgasmia in OCD patients.
- Sexual side effects like anorgasmia can be significant and may go unnoticed without structured assessment, potentially limiting the therapeutic benefit of clomipramine.